Stock RAM RAMKHAMHAENG HOSPITAL
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ramkhamhaeng Hospital

Equities

RAM

TH0259A10Z01

End-of-day quote Thailand S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
31.25 THB -1.57% Intraday chart for Ramkhamhaeng Hospital +1.63% -13.19%
Mar. 21 Ramkhamhaeng Hospital Public Company Limited Announces Executive Changes CI
Mar. 15 Ramkhamhaeng Hospital Public Company Limited Proposes Fourth Interim Dividend, Payable on 29 May 2024 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The group's high margin levels account for strong profits.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The firm trades with high earnings multiples: 25.9 times its 2024 earnings per share.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
RAMKHAMHAENG HOSPITAL Stock Ramkhamhaeng Hospital
-13.19% 1.01B -
CVS HEALTH CORPORATION Stock CVS Health Corporation
-28.69% 85.35B
B-
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+14.32% 81.95B
C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+9.37% 28.99B
C+
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-11.43% 16.98B
B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-0.36% 16.85B
A-
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-0.24% 15.35B
A-
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+4.32% 12.42B
A-
DAVITA INC. Stock DaVita Inc.
+33.40% 12.19B
B-
PURE HEALTH HOLDING Stock Pure Health Holding
-31.40% 11.89B - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. RAM Stock
  4. Ratings Ramkhamhaeng Hospital